NO995134L - Forbedrede fremgangsmåter for fremstilling av aktivert protein C - Google Patents

Forbedrede fremgangsmåter for fremstilling av aktivert protein C

Info

Publication number
NO995134L
NO995134L NO995134A NO995134A NO995134L NO 995134 L NO995134 L NO 995134L NO 995134 A NO995134 A NO 995134A NO 995134 A NO995134 A NO 995134A NO 995134 L NO995134 L NO 995134L
Authority
NO
Norway
Prior art keywords
preparation
activated protein
improved methods
protein
activated
Prior art date
Application number
NO995134A
Other languages
English (en)
Norwegian (no)
Other versions
NO995134D0 (no
Inventor
Jeffrey Clayton Baker
Andrew David Carlson
Lihua Huang
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995134D0 publication Critical patent/NO995134D0/no
Publication of NO995134L publication Critical patent/NO995134L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO995134A 1997-04-28 1999-10-21 Forbedrede fremgangsmåter for fremstilling av aktivert protein C NO995134L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
PCT/US1998/008384 WO1998048822A1 (en) 1997-04-28 1998-04-24 Improved methods for processing activated protein c

Publications (2)

Publication Number Publication Date
NO995134D0 NO995134D0 (no) 1999-10-21
NO995134L true NO995134L (no) 1999-12-21

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
NO995134A NO995134L (no) 1997-04-28 1999-10-21 Forbedrede fremgangsmåter for fremstilling av aktivert protein C
NO995198A NO995198D0 (no) 1997-04-28 1999-10-25 Aktiverte protein C-formuleringer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO995198A NO995198D0 (no) 1997-04-28 1999-10-25 Aktiverte protein C-formuleringer

Country Status (34)

Country Link
US (4) US6159468A (2)
EP (2) EP0875563A3 (2)
JP (2) JP4383546B2 (2)
KR (2) KR100564189B1 (2)
CN (2) CN1235638C (2)
AR (2) AR015598A1 (2)
AT (1) ATE285788T1 (2)
AU (2) AU740753C (2)
BR (2) BR9809304B1 (2)
CA (2) CA2287267C (2)
CO (2) CO4950523A1 (2)
CZ (1) CZ298429B6 (2)
DE (1) DE69828330T2 (2)
DK (1) DK0875252T3 (2)
EA (2) EA004881B1 (2)
EG (1) EG23685A (2)
ES (1) ES2234072T3 (2)
HU (2) HU224826B1 (2)
ID (2) ID22933A (2)
IL (2) IL132325A (2)
IN (2) IN183798B (2)
MY (2) MY120984A (2)
NO (2) NO995134L (2)
NZ (2) NZ500346A (2)
PE (2) PE86299A1 (2)
PL (2) PL195090B1 (2)
PT (1) PT875252E (2)
SI (1) SI0875252T1 (2)
SV (2) SV1998000051A (2)
TR (2) TR199902529T2 (2)
TW (2) TW585871B (2)
UA (2) UA55448C2 (2)
WO (2) WO1998048818A1 (2)
ZA (2) ZA983497B (2)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
UA55448C2 (uk) 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
AU1477000A (en) * 1998-11-13 2000-06-05 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
EP1133314B1 (en) * 1998-11-23 2003-02-19 Eli Lilly And Company Protein c for the treatment of sickle cell disease and thalassemia
IL142249A0 (en) * 1998-12-10 2002-03-10 Lilly Co Eli Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
US20030055003A1 (en) * 2001-07-19 2003-03-20 David Bar-Or Use of copper chelators to inhibit the inactivation of protein C
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
EP1562626B1 (en) * 2002-10-29 2007-11-28 ALZA Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
ES2386972T3 (es) * 2006-05-31 2012-09-10 Genzyme Corporation Uso de polisacáridos para la estimulación de la actividad enzimática
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
EP2117514B1 (en) * 2007-03-05 2011-06-15 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
CA2681752A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
UA55448C2 (uk) * 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
IL132325A0 (en) 2001-03-19
PE86299A1 (es) 1999-09-17
HUP0100284A2 (hu) 2001-06-28
IN183798B (2) 2000-04-15
JP4383547B2 (ja) 2009-12-16
DK0875252T3 (da) 2005-04-25
CA2288143C (en) 2012-08-21
TR199902631T2 (xx) 2000-01-21
TW585871B (en) 2004-05-01
HUP0100284A3 (en) 2003-08-28
TR199902529T2 (xx) 2000-02-21
NO995198L (no) 1999-10-25
CN1235638C (zh) 2006-01-11
KR100564189B1 (ko) 2006-03-27
AR012010A1 (es) 2000-09-13
EA004881B1 (ru) 2004-08-26
CA2287267C (en) 2006-08-15
US6436397B1 (en) 2002-08-20
MY118591A (en) 2004-12-31
PL336889A1 (en) 2000-07-17
AU740753C (en) 2002-10-10
HUP0003401A2 (hu) 2001-02-28
ID23172A (id) 2000-03-23
CO4950523A1 (es) 2000-09-01
US6159468A (en) 2000-12-12
HK1016472A1 (en) 1999-11-05
UA55448C2 (uk) 2003-04-15
AU7161898A (en) 1998-11-24
HUP0003401A3 (en) 2003-01-28
JP4383546B2 (ja) 2009-12-16
WO1998048822A1 (en) 1998-11-05
EP0875563A2 (en) 1998-11-04
CZ381099A3 (cs) 2000-03-15
EP0875252A3 (en) 2000-07-26
NO995198D0 (no) 1999-10-25
PT875252E (pt) 2005-03-31
EG23685A (en) 2007-05-09
PL336420A1 (en) 2000-06-19
ES2234072T3 (es) 2005-06-16
AR015598A1 (es) 2001-05-16
ATE285788T1 (de) 2005-01-15
AU743531B2 (en) 2002-01-31
SV1998000050A (es) 1999-01-13
US6395270B1 (en) 2002-05-28
JP2001524111A (ja) 2001-11-27
ID22933A (id) 1999-12-16
BR9809304B1 (pt) 2011-02-08
CA2287267A1 (en) 1998-11-05
EA199900980A1 (ru) 2000-04-24
EA199900979A1 (ru) 2000-06-26
CZ298429B6 (cs) 2007-10-03
US6162629A (en) 2000-12-19
EA002149B1 (ru) 2001-12-24
MY120984A (en) 2005-12-30
IL132325A (en) 2005-07-25
EP0875252B1 (en) 2004-12-29
NZ337828A (en) 2001-06-29
AU740753B2 (en) 2001-11-15
CN1227025C (zh) 2005-11-16
EP0875252A2 (en) 1998-11-04
TWI242443B (en) 2005-11-01
CO4940438A1 (es) 2000-07-24
IN187157B (2) 2002-02-16
NZ500346A (en) 2001-08-31
CA2288143A1 (en) 1998-11-05
ZA983497B (en) 1999-10-25
KR20010020242A (ko) 2001-03-15
PE84799A1 (es) 1999-09-16
CN1254284A (zh) 2000-05-24
KR100450856B1 (ko) 2004-10-02
PL195090B1 (pl) 2007-08-31
KR20010020325A (ko) 2001-03-15
DE69828330D1 (de) 2005-02-03
AU7258998A (en) 1998-11-24
NO995134D0 (no) 1999-10-21
SI0875252T1 (en) 2005-06-30
JP2001527543A (ja) 2001-12-25
IL132502A0 (en) 2001-03-19
PL195642B1 (pl) 2007-10-31
DE69828330T2 (de) 2005-10-13
CN1261280A (zh) 2000-07-26
HU224826B1 (en) 2006-02-28
BR9809292A (pt) 2000-07-04
ZA983496B (en) 1999-10-25
BR9809304A (pt) 2000-10-17
UA73071C2 (en) 2005-06-15
WO1998048818A1 (en) 1998-11-05
SV1998000051A (es) 1998-12-11
EP0875563A3 (en) 2000-08-02

Similar Documents

Publication Publication Date Title
NO995134L (no) Forbedrede fremgangsmåter for fremstilling av aktivert protein C
NO994757D0 (no) FramgangsmÕte for oral administrasjon av proteiner
NO990059D0 (no) Analoger av kationiske proteiner
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
NO986202L (no) FremgangsmÕte for fremstilling av rekombinant adÚnovirus
ID16866A (id) Kompleks kompleks inklusi garam-garam aril-heterosiklik
PT892640E (pt) Composicoes farmaceuticas de micofenolato entericamente revestidas
NO983364L (no) Konsensusproteiner
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
IS5245A (is) Lyfjablanda úr ómeprasól
NO963049L (no) Modulatorer av forankrende proteinfunksjon
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
NO986177D0 (no) FremgangsmÕte for fremstilling av terapeutisk DNA
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
EP1012262A4 (en) Human frezzled-like protein
EE200000055A (et) Protsess tsüklopropüülatsetüleeni valmistamiseks
DE69837507D1 (de) Humanes Hedgehog-Protein
NO20001777D0 (no) Fremgangsmåte for fremstilling av substituerte 4-fenyl-4- cyanocykloheksankarboksylsyrer
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
EP1140121A4 (en) CRYOGRANULATION OF ACTIVATED PROTEIN C
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
NO991148L (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod
NO20003077L (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO20002476D0 (no) FremgangsmÕte for fremstilling av formylimidazoler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application